OBJECTIVE: To assess the prognostic value of clinical and biological variables in the era of targeted therapies, especially induced toxicity in patients treated for metastatic renal cell carcinoma (RCC).
PATIENTS AND METHODS: A retrospective single-center study was performed in patients treated in our center from 2006 to 2012. The clinical and biological variables and toxicity data were retrospectively collected. Survival rates were calculated using the Kaplan-Meier method and compared by the Log-Rank test. Multivariate analysis was also performed using the Cox model.
RESULTS: One hundred and two patients were included, with a median follow-up of 20 months. The median overall survival (OS) was 21 months, and 6 months for the progression free survival (PFS). As expected, the variables included in the Mozter prognostic score had a significant impact on OS (P < 0.0001) and PFS (P < 0.0001). However, hypoalbuminemia (P < 0.0001), brain metastasis (P = 0.003) and the absence of nephrectomy (P < 0.0001) were found as poor prognosis factors for OS. In addition, severe toxicity (grade 3-4) was significantly associated with higher OS (P < 0.0001) and PFS (P = 0.0003) and appeared as an independent factor in multivariate analysis for OS (P = 0.02) and PFS (P = 0.01).
CONCLUSION: Severe toxicity induced by targeted therapies was found as a prognostic factor increasing significantly the survival. Further studies are needed to assess the real value of this factor in the development of sequential therapies for the treatment of RCC.
Written by:
Nouhaud FX, Rebibo JD, Blanchard F, Sabourin JC, Di Fiore F, Pfister C. Are you the author?
Service d'urologie, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France; Service d'anatomie et cytologie pathologique, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France; Service d'oncologie urologique et digestive, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France; Service d'oncologie médicale, centre Henri-Becquerel, rue d'Amiens, 76000 Rouen, France.
Reference: Prog Urol. 2014 Jul;24(9):563-71.
doi: 10.1016/j.purol.2013.12.001
PubMed Abstract
PMID: 24975791
UroToday.com Renal Cancer Section
